Article
Obstetrics & Gynecology
Willem Jan van Weelden, Roy I. Lalisang, Johan Bulten, Kristina Lindemann, Heleen J. van Beekhuizen, Hans Trum, Dorry Boll, Henrica M. J. Werner, Luc R. C. W. van Lonkhuijzen, Refika Yigit, David Forsse, Petronella O. Witteveen, Khadra Galaal, Alexandra van Ginkel, Eliana Bignotti, Vit Weinberger, Sanne Sweegers, Judith R. Kroep, Silvia Cabrera, Marc P. L. M. Snijders, Marcia A. Inda, Ane Gerda Z. Eriksson, Camilla Krakstad, Andrea Romano, Anja van de Stolpe, Johanna M. A. Pijnenborg
Summary: This study aimed to improve the efficacy of hormonal therapy in advanced or recurrent endometrial cancer by analyzing hormone receptor expressions and pathway activity. Results showed that using a 50% cutoff level for hormone receptor expression significantly enhanced the prediction of response to hormonal treatment.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
(2021)
Review
Oncology
Jing Xu, Bo Cao, Chunyu Li, Guohui Li
Summary: Breast cancer is a global health concern. Endocrine therapy is crucial in treating estrogen-positive breast cancer, but it often leads to osteoporosis-related adverse events. These events increase the risk of fractures and reduce the patients' quality of life. This review explores the possibility of endocrine therapy-induced osteoporosis in estrogen-positive breast cancer treatment and discusses the mechanisms involved and the potential of drug therapies and combinations.
FRONTIERS IN ONCOLOGY
(2023)
Article
Neurosciences
Alev Selek, Zehra Seda Unal Halbutogullari, Cigdem Inci Aydemir, Berrin Cetinarslan, Zeynep Canturk, Ilhan Tarkun, Gulay Erman, Cansu Subasi, Karaoz Erdal
Summary: This study investigates the potential of using an aromatase inhibitor as a substitute for testosterone in treating prolactinomas. The findings reveal that the aromatase inhibitor can inhibit cell proliferation and induce apoptosis in prolactinoma cells, as well as reduce prolactin and estrogen levels.
MOLECULAR NEUROBIOLOGY
(2023)
Review
Oncology
Saikat Mitra, Mashia Subha Lami, Avoy Ghosh, Rajib Das, Trina Ekawati Tallei, Fatimawali, Fahadul Islam, Kuldeep Dhama, M. Yasmin Begum, Afaf Aldahish, Kumarappan Chidambaram, Talha Bin Emran
Summary: Hormone therapy is a common treatment approach for severe and recurrent gynecological cancers, and it works by reducing hormone levels or inhibiting their biological activity. This therapy has shown promising results in halting or slowing cancer progression. However, the response rates and therapeutic effects vary among patients. Therefore, this review explores the use of hormonal therapies for gynecological cancers and identifies the current gaps in knowledge.
Article
Oncology
Sara Caceres, Beatriz Monsalve, Angela Alonso-Diez, Belen Crespo, Maria Jose Illera, Paloma Jimena de Andres, Gema Silvan, Juan Carlos Illera
Summary: Through experimental studies on canine and human inflammatory breast cancer, it was found that anti-aromatase and anti-sulfatase therapies have inhibitory effects on tumors in vitro, while anti-sulfatase can increase tumor progression; letrozole effectively reduces tumor progression by decreasing estrogen levels.
Review
Medicine, Research & Experimental
Manar A. Eissa, Eman Y. Gohar
Summary: The documented differences in cardiovascular and chronic kidney diseases risk between males and females are largely attributed to the role of estrogens. Estrogens exert cardiovascular and renal protective effects through the activation of estrogen receptors and interactions with the renin-angiotensin-aldosterone system. Aromatase, an enzyme involved in the conversion of androgens into estrogens, plays a crucial role in estrogen biosynthesis. The use of aromatase inhibitors to treat estrogen-related pathologies may be associated with cardiovascular events. The potential contribution of aromatase enzyme to cardio-renal protection is highlighted in this review.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Health Care Sciences & Services
Barbara Gardella, Mattia Dominoni, Stefano Bogliolo, Chiara Cassani, Giulia Vittoria Carletti, Annalisa De Silvestri, Arsenio Spinillo
Summary: This study aimed to test the feasibility and safety of anastrozole as palliative treatment for elderly women with type I endometrial cancer not suitable for surgery. Results showed that most patients had a partial response to the therapy, with improved symptoms and no disease progression observed during the study period.
BMC PALLIATIVE CARE
(2021)
Review
Oncology
Rumeysa Ozyurt, Bulent Ozpolat
Summary: Estrogen receptor-positive (ER+) breast cancer is a common cause of cancer-related deaths in women globally. While anti-estrogen therapies have improved survival rates, around 60% of patients experience resistance to these treatments, leading to disease recurrence, metastasis, and mortality. Understanding the mechanisms of treatment resistance and developing new therapeutic strategies is crucial for improving patient outcomes.
Review
Oncology
Vincent M. Wagner, Floor J. Backes
Summary: Endometrial cancer is a common gynecologic cancer with poor prognosis in recurrent cases. Hormonal therapy, including progesterones and agents targeting the estrogen pathway, is an effective option for patients with low-grade hormone receptor-positive disease who cannot tolerate or prefer to avoid cytotoxic chemotherapy or other targeted therapies. Molecular profiling and ongoing trials are exploring novel hormonal therapy agents.
Review
Oncology
Angiolo Gadducci, Stefania Cosio
Summary: Patients with metastatic or recurrent endometrial cancer who are not suitable for surgery and/or radiotherapy often have unsatisfactory clinical outcomes with pharmacological treatment. The combination of carboplatin + paclitaxel is the standard first-line chemotherapy, while hormonal therapy is sometimes used for steroid receptor-positive EC patients. Immune checkpoint inhibitors, such as pembrolizumab and dostarlimab, have shown good objective responses in highly pretreated patients with MMR-deficient EC.
Article
Cell Biology
Nahla M. Badr, David Spooner, Jane Steven, Andrea Stevens, Abeer M. Shaaban
Summary: This study investigated the effect of NAET on tumour type, grade, and molecular profile in breast cancer patients. Significant changes were observed, including complete pathological response in some cases, central scarring in almost half of the tumours post-treatment, and downgrading of tumour grade in one-third of cases. The study suggests a histological method for assessing residual carcinoma after NAET and recommends repeat ER/PR/HER2 testing for management and prognosis.
Article
Oncology
Panagiotis A. Konstantinopoulos, Elizabeth K. Lee, Niya Xiong, Carolyn Krasner, Susana Campos, David L. Kolin, Joyce F. Liu, Neil Horowitz, Alexi A. Wright, Sara Bouberhan, Richard T. Penson, Oladapo Yeku, Brittany Bowes, Hope Needham, Martin Hayes, Hannah Sawyer, Madeline Polak, Meghan Shea, Su-Chun Cheng, Cesar Castro, Ursula A. Matulonis
Summary: The combination therapy of Letrozole and Abemaciclib showed promising and durable activity in recurrent ER-positive endometrial cancers, indicating its potential as a treatment option for this subtype of cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Michelino De Laurentiis, Roberta Caputo, Manuelita Mazza, Mauro Mansutti, Riccardo Masetti, Zelmira Ballatore, Rosalba Torrisi, Andrea Michelotti, Alberto Zambelli, Antonella Ferro, Daniele Generali, Patrizia Vici, Luigi Coltelli, Alessandra Fabi, Paolo Marchetti, Alberto Ballestrero, Simon Spazzapan, Antonio Frassoldati, Maria Giuseppina Sarobba, Donatella Grasso, Claudio Zamagni
Summary: In the Italian subpopulation, the safety and efficacy profiles of Ribociclib plus letrozole were consistent with the global study results, reaffirming it as a frontline treatment option for patients with HR+, HER2- ABC.
Article
Chemistry, Medicinal
Lilan Xin, Jian Min, Hebing Hu, Yuanyuan Li, Chuanqian Du, Baohua Xie, Yan Cheng, Xiaofei Deng, Xiangping Deng, Kang Shen, Jian Huang, Chun -Chi Chen, Rey-Ting Guo, Chune Dong, Hai -Bing Zhou
Summary: In this study, a novel class of dual-targeting selective estrogen receptor degraders (SERDs) based on a three-dimensional oxabicycloheptene sulfonamide (OBHSA) scaffold equipped with aromatase inhibitor (AI) activity were identified. These compounds showed excellent ERa degradation activity, ARO inhibitory activity, and antiproliferative activity against drug-resistant breast cancer cells.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Review
Pharmacology & Pharmacy
Keerti Mishra, Pooja Ratre, Suresh Thareja, Akhlesh K. Jain
Summary: Breast cancer is emerging worldwide with an alarming rate, specifically in post-menopausal women, and it is mostly caused because of estrogen. Aromatase inhibitors and estrogen synthesis inhibitors could prevent chances of breast cancer.
CURRENT PHARMACEUTICAL DESIGN
(2021)
Article
Oncology
Yingmei Wang, Chao Gao, Yanfang Zhang, Jinping Gao, Fei Teng, Wenyan Tian, Wen Yang, Ye Yan, Fengxia Xue
GYNECOLOGIC ONCOLOGY
(2016)
Article
Obstetrics & Gynecology
Yingmei Wang, Cha Han, Fei Teng, Zhaoyi Bai, Wenyan Tian, Fengxia Xue
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
(2017)
Article
Oncology
Fei Teng, Wen-Yan Tian, Ying-Mei Wang, Yan-Fang Zhang, Fei Guo, Jing Zhao, Chao Gao, Feng-Xia Xue
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2016)
Review
Oncology
Chao Gao, Yingmei Wang, Russell Broaddus, Longhao Sun, Fengxia Xue, Wei Zhang
Review
Oncology
Mengting Dong, Su Jiang, Wenyan Tian, Ye Yan, Chao Gao, Jinping Gao, Yan Sheng, Yingmei Wang, Fengxia Xue
CANCER BIOLOGY & THERAPY
(2018)
Review
Oncology
Yuqin Zang, Mengting Dong, Kai Zhang, Chao Gao, Fei Guo, Yingmei Wang, Fengxia Xue
Article
Oncology
Fei Guo, Kai Zhang, Meiyue Li, Lei Cui, Guoyan Liu, Ye Yan, Wenyan Tian, Fei Teng, Yanfang Zhang, Chao Gao, Jinping Gao, Yingmei Wang, Fengxia Xue
INTERNATIONAL JOURNAL OF ONCOLOGY
(2020)
Review
Biochemistry & Molecular Biology
Chao Gao, Yanyan Han, Lu Bai, Yingmei Wang, Fengxia Xue
Summary: IK is a novel regulator of cell mitosis that may contribute to carcinogenesis by inducing mitotic arrest and cell death, as well as modulating the tumor immune microenvironment. Understanding the biological functions and mechanisms of IK in cancer provides insights into its clinical significance in future perspectives.
CELL BIOCHEMISTRY AND FUNCTION
(2021)
Article
Oncology
Chao Gao, Guangxu Jin, Elizabeth Forbes, Lingegowda S. Mangala, Yingmei Wang, Cristian Rodriguez-Aguayo, Paola Amero, Emine Bayraktar, Ye Yan, Gabriel Lopez-Berestein, Russell R. Broaddus, Anil K. Sood, Fengxia Xue, Wei Zhang
Summary: Research found that IK somatic mutations are more common in high-grade and high-stage endometrial cancer patients, who have longer survival periods. These mutations are related to the pathophysiology of EC and have a role in promoting cell cycle progression.
Review
Oncology
Jiali Hu, Ke Li, Zhanghuan Li, Chao Gao, Fei Guo, Yingmei Wang, Fengxia Xue
CANCER BIOLOGY & MEDICINE
(2019)
Article
Oncology
Wenyan Tian, Fei Teng, Jinping Gao, Chao Gao, Guoyan Liu, Yanfang Zhang, Shizhu Yu, Wei Zhang, Yingmei Wang, Fengxia Xue
CANCER BIOLOGY & MEDICINE
(2019)
Article
Oncology
Wenyan Tian, Fei Teng, Jing Zhao, Jinping Gao, Chao Gao, Dandan Sun, Guoyan Liu, Yanfang Zhang, Shizhu Yu, Wei Zhang, Yingmei Wang, Fengxia Xue
CANCER BIOLOGY & THERAPY
(2017)
Article
Oncology
Jinping Gao, Jintian Zhang, Wenyan Tian, Fei Teng, Huiying Zhang, Xuhong Zhang, Yingmei Wang, Fengxia Xue
CANCER BIOLOGY & THERAPY
(2017)
Article
Cell Biology
Longhao Sun, Limei Hu, David Cogdell, Li Lu, Chao Gao, Weijun Tian, Zhixiang Zhang, Ya'an Kang, Jason B. Fleming, Wei Zhang
Article
Oncology
Fei Teng, Xiaotong Ma, Xiaopei Yu, Ye Yan, Jing Zhao, Jinping Gao, Chao Gao, Yingmei Wang, Wenyan Tian, Fengxia Xue
Article
Oncology
Dimitrios Nasioudis, Stefan Gysler, Nawar Latif, Lory Cory, Robert L. Giuntoli II, Sarah H. Kim, Fiona Simpkins, Lainie Martin, Emily M. Ko
Summary: The prevalence of ERBB2 gene amplification was investigated among patients with gynecologic malignancies. The study found that ERBB2 amplification is frequently encountered in uterine serous carcinoma and mucinous ovarian carcinoma, but less common in endometrioid endometrial carcinoma.
GYNECOLOGIC ONCOLOGY
(2024)